T. Wengenack

发表

In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent

Michael Garwood, Clifford R Jack, Gregor Adriany, 2004, Magnetic resonance in medicine.

In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice

Clifford R Jack, Gregor Adriany, Michael Garwood, 2005, The Journal of Neuroscience.

Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy.

Clifford R Jack, Michael Garwood, Kâmil Ugurbil, 2005, Proceedings of the National Academy of Sciences of the United States of America.

MR Microimaging of amyloid plaques in Alzheimer’s disease transgenic mice

Clifford R. Jack, Michael Garwood, C. Jack, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

Targeting Vascular Amyloid in Arterioles of Alzheimer Disease Transgenic Mice With Amyloid &bgr; Protein Antibody-Coated Nanoparticles

Ryan Chamberlain, Clifford R Jack, Michael Garwood, 2011, Journal of neuropathology and experimental neurology.

Treatment effects in a transgenic mouse model of Alzheimer’s disease: A magnetic resonance spectroscopy study after passive immunization

G. L. Curran, C. Jack, S. Weigand, 2014, Neuroscience.

Multidisciplinary Assessments of Visual and Psychomotor Functions Essential for Driving in the Elderly

William P. Dunlap, T. M. Wengenack, J. M. Ordy, 1991 .

Visual Acuity, Aging, and Environmental Interactions: A Neuroscience Perspective

W. Dunlap, J. Ordy, T. Wengenack, 1991 .

Mutant mice with small amounts of BubR1 display accelerated age-related gliosis

J. Deursen, T. Wengenack, J. Poduslo, 2007, Neurobiology of Aging.

In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques

M. Ramirez-Alvarado, G. Curran, T. Wengenack, 2007, Journal of neurochemistry.

Selective Contrast Enhancement of Individual Alzheimer’s Disease Amyloid Plaques Using a Polyamine and Gd-DOTA Conjugated Antibody Fragment Against Fibrillar Aβ42 for Magnetic Resonance Molecular Imaging

M. Garwood, M. Ramirez-Alvarado, C. Jack Jr., 2008, Pharmaceutical Research.

Pharmacokinetic Analysis of the Blood-Brain Barrier Transport of 125I-Amyloid β Protein 40 in Wild-Type and Alzheimer's Disease Transgenic Mice (APP,PS1) and Its Implications for Amyloid Plaque Formation

G. Curran, T. Wengenack, J. Poduslo, 2005, Journal of Pharmacology and Experimental Therapeutics.

Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.

G. Curran, T. Wengenack, J. Poduslo, 2004, Biochemistry.

Therapeutic benefit of polyamine‐modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics

G. Curran, T. Wengenack, J. Poduslo, 2000, Annals of neurology.

A Carrier for Non-Covalent Delivery of Functional Beta-Galactosidase and Antibodies against Amyloid Plaques and IgM to the Brain

V. Lowe, R. Jenkins, G. Sarkar, 2011, PloS one.

Selective Vulnerability and Early Progression of Hippocampal CA1 Pyramidal Cell Degeneration and GFAP-Positive Astrocyte Reactivity in the Rat Four-Vessel Occlusion Model of Transient Global Ischemia

W. Dunlap, P. Coleman, J. Ordy, 1993, Experimental Neurology.

Putrescine-modified catalase with preserved enzymatic activity exhibits increased permeability at the blood-nerve and blood-brain barriers

G. L. Curran, T. Wengenack, J. Poduslo, 1997, Brain Research.

Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia

G. Curran, T. Wengenack, J. Poduslo, 1997, Brain Research.

Vascular and cellular protein changes precede hippocampal pyramidal cell loss following global ischemia in the rat.

W. Dunlap, P. Coleman, J. Ordy, 1994, Advances in experimental medicine and biology.

Camstatins Are Peptide Antagonists of Calmodulin Based Upon a Conserved Structural Motif in PEP-19, Neurogranin, and Neuromodulin*

S. Fullerton, J. Morgan, B. Hilbush, 1996, The Journal of Biological Chemistry.

Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease.

Ryan Chamberlain, Michael Garwood, Clifford R Jack, 2011, Current medical imaging reviews.

Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging

Thomas Wisniewski, Clifford R. Jack, Bret J. Borowski, 2002, Neurobiology of Disease.

Phenotype and age differences in blood gas characteristics, electrolytes, hemoglobin, plasma glucose and cortisol in female squirrel monkeys.

W. Dunlap, J. Ordy, T. Wengenack, 1988, Laboratory animal science.

Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice

Karunya K. Kandimalla, C. Montano, G. Curran, 2005, Brain Research.

Profiling of endogenous peptides as a tool for studying development and neurological disease.

D. Flood, T. Wengenack, J. Slemmon, 1997, Biopolymers.

Defects in Mitochondrial Dynamics and Metabolomic Signatures of Evolving Energetic Stress in Mouse Models of Familial Alzheimer's Disease

P. Dzeja, E. Nemutlu, Song Zhang, 2012, PloS one.

Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain

K. Duff, G. Curran, T. Wengenack, 2000, Neuroscience.

Pharmacokinetics and Amyloid Plaque Targeting Ability of a Novel Peptide-Based Magnetic Resonance Contrast Agent in Wild-Type and Alzheimer's Disease Transgenic Mice

G. Curran, T. Wengenack, J. Poduslo, 2007, Journal of Pharmacology and Experimental Therapeutics.

Physiological and Biophysical Factors That Influence Alzheimer's Disease Amyloid Plaque Targeting of Native and Putrescine Modified Human Amyloid β40

M. Ramirez-Alvarado, G. Curran, T. Wengenack, 2006, Journal of Pharmacology and Experimental Therapeutics.

Permeability of Proteins at the Blood–Brain Barrier in the Normal Adult Mouse and Double Transgenic Mouse Model of Alzheimer's Disease

K. Duff, G. Curran, T. Wengenack, 2001, Neurobiology of Disease.

Targeting Alzheimer amyloid plaques in vivo

G. Curran, T. Wengenack, J. Poduslo, 2000, Nature Biotechnology.

Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research

Clifford R Jack, Michael Garwood, G. L. Curran, 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

Reduced Membrane Lipids in the Cortex of Alzheimer’s Disease Transgenic Mice

Jeffrey K. Yao, G. Curran, T. Wengenack, 2008, Neurochemical Research.

Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain

Clifford R. Jack, Bret J. Borowski, J. Lin, 2011, NeuroImage.

Comparison of amyloid plaque contrast generated by T2‐weighted, T 2* ‐weighted, and susceptibility‐weighted imaging methods in transgenic mouse models of Alzheimer's disease

Ryan Chamberlain, Clifford R Jack, Michael Garwood, 2009, Magnetic resonance in medicine.

HH Domain of Alzheimer’s Disease Aβ Provides Structural Basis for Neuronal Binding in PC12 and Mouse Cortical/Hippocampal Neurons

G. Curran, T. Wengenack, J. Poduslo, 2010, PloS one.

Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid β peptide capturing- and plaque binding-monoclonal antibodies

T. Wengenack, J. Poduslo, Thomas M Wengenack, 2009, Alzheimer's & Dementia.

Activation of programmed cell death markers in ventral horn motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in a transgenic mouse model

C. Montano, G. Curran, T. Wengenack, 2004, Brain Research.

Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid β peptide capturing- and plaque binding-monoclonal antibodies

Karunya K. Kandimalla, Joseph F. Poduslo, Thomas M. Wengenack, 2010, Alzheimer's & Dementia.

Quantitative analysis of peptide and protein changes in ischemic hippocampal tissue by HPLC.

J. Ordy, T. Wengenack, J. Slemmon, 1998, Methods in molecular biology.

Pharmacological Effects of Remacemide and MK-801 on Memory and Hippocampal CA1 Damage in the Rat Four-Vessel Occlusion (4-VO) Model of Global Ischemia

B. Volpe, G. J. Thomas, W. Dunlap, 1992 .

Comparison of amyloid plaque contrast generated by T2‐weighted, T 2* ‐weighted, and susceptibility‐weighted imaging methods in transgenic mouse models of Alzheimer's disease

G. L. Curran, C. Jack, M. Garwood, 2009, Magnetic resonance in medicine.